Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug aims to tame Graves' disease Long-Term

NCT ID NCT07286006

Disease control Sponsor: Immunovant Sciences GmbH Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jul 28, 2026 · Updated 3 times

Summary

This study tests a drug called IMVT-1402 in adults with Graves' disease, a condition where the immune system attacks the thyroid. The goal is to see if the drug can help patients stay healthy without needing other treatments. About 372 people who completed earlier studies will take the drug for up to 52 weeks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
IMVT-1402
What this could lead to
If successful, this could point toward a way to keep Graves' disease under control without needing lifelong medication.
What could go wrong
This is an early phase 2 extension study, so results are not yet proven. The drug may not work for everyone, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 372 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Mar 2030

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants who completed Study IMVT-1402-2502 or Study IMVT-1402-2503. * Other, more specific inclusion criteria are defined in the protocol. Exclusion Criteria: * Have permanently discontinued IMP during the treatment period in the feeder study or have met study stopping criteria at any point up until the end of participation in the feeder study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Graves disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Graves disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Graves disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    105 sites in 7 countries. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Site Number - 1500

    Morehead City, North Carolina, 28557, United States

  • Site Number - 1501

    Mesquite, Texas, 75149, United States

  • Site Number - 1502

    El Paso, Texas, 79935, United States

  • Site Number - 1503

    Farmington Hills, Michigan, 33186, United States

  • Site Number - 1504

    Fort Worth, Texas, 76132, United States

  • Site Number - 1505

    Miami, Florida, 33143, United States

  • Site Number - 1506

    Hickory, North Carolina, 28601, United States

  • Site Number - 1507

    Port Charlotte, Florida, 33952, United States

  • Site Number - 1508

    Orlando, Florida, 32819, United States

  • Site Number - 1509

    Chapel Hill, North Carolina, 27514, United States

  • Site Number - 1510

    Concord, California, 94520, United States

  • Site Number - 1511

    Jefferson City, Missouri, 65109-6023, United States

  • Site Number - 1512

    Las Vegas, Nevada, 89148, United States

  • Site Number - 1513

    Dallas, Texas, 75208, United States

  • Site Number - 1515

    Rochester, Minnesota, 55905, United States

  • Site Number - 1516

    Newark, Delaware, 19713, United States

  • Site Number - 1517

    Austin, Texas, 78731, United States

  • Site Number - 1518

    Stockbridge, Georgia, 30281, United States

  • Site Number - 1519

    Phoenix, Arizona, 85015, United States

  • Site Number - 1520

    Round Rock, Texas, 78681, United States

  • Site Number - 1521

    Omaha, Nebraska, 68105, United States

  • Site Number - 1522

    Doral, Florida, 33166, United States

  • Site Number - 1523

    Hialeah, Florida, 33016, United States

  • Site Number - 1524

    Memphis, Tennessee, 38119, United States

  • Site Number - 1525

    Irving, Texas, 75039, United States

  • Site Number - 1526

    Columbus, Georgia, 31904, United States

  • Site Number - 1527

    San Antonio, Texas, 78231, United States

  • Site Number - 1528

    Reno, Nevada, 89511, United States

  • Site Number - 1529

    McKinney, Texas, 75069, United States

  • Site Number - 1530

    Tucson, Arizona, 85710, United States

  • Site Number - 1531

    New York, New York, 10022, United States

  • Site Number - 1532

    San Antonio, Texas, 78229, United States

  • Site Number - 1533

    Aurora, Colorado, 80045, United States

  • Site Number - 1534

    Topeka, Kansas, 66606, United States

  • Site Number - 1535

    Norfolk, Virginia, 23507, United States

  • Site Number - 1536

    Oklahoma City, Oklahoma, 73118, United States

  • Site Number - 1537

    Kansas City, Missouri, 64108, United States

  • Site Number - 1538

    Dallas, Texas, 75246, United States

  • Site Number - 1539

    New York, New York, 11106, United States

  • Site Number - 1540

    Raleigh, North Carolina, 27612, United States

  • Site Number - 1542

    Williamsville, New York, 14221, United States

  • Site Number - 1544

    New Hyde Park, New York, 11042, United States

  • Site Number - 1546

    Louisville, Kentucky, 40202, United States

  • Site Number - 1548

    West Palm Beach, Florida, 33401, United States

  • Site Number - 1549

    Portland, Oregon, 97035, United States

  • Site Number - 1550

    Summerville, South Carolina, 29485, United States

  • Site Number - 1551

    Dallas, Texas, 75231, United States

  • Site Number - 1552

    Torrance, California, 90509, United States

  • Site Number - 1553

    San Antonio, Texas, 78215, United States

  • Site Number - 1554

    Los Angeles, California, 90033, United States

  • Site Number - 1555

    New Orleans, Louisiana, 70112, United States

  • Site Number - 1556

    Clearwater, Florida, 33756, United States

  • Site Number - 1557

    Boston, Massachusetts, 32216, United States

  • Site Number - 1558

    Santa Clarita, California, 91321, United States

  • Site Number - 1559

    San Francisco, California, 94143, United States

  • Site Number - 1560

    Philadelphia, Pennsylvania, 19140, United States

  • Site Number - 1561

    Phoenix, Arizona, 85006, United States

  • Site Number - 1562

    Indianapolis, Indiana, 46202, United States

  • Site Number - 1563

    Salt Lake City, Utah, 84108, United States

  • Site Number - 1564

    Miami, Florida, 39501, United States

  • Site Number - 1565

    Baltimore, Maryland, 21287, United States

  • Site Number - 1566

    Atlanta, Georgia, 30318, United States

  • Site Number - 1567

    Washington D.C., District of Columbia, 20010, United States

  • Site Number - 1568

    Kansas City, Kansas, 66210, United States

  • Site Number - 1569

    Chattanooga, Tennessee, 37421, United States

  • Site Number - 1570

    Pottstown, Pennsylvania, 19464, United States

  • Site Number - 1571

    Bowling Green, Kentucky, 42101, United States

  • Site Number - 1575

    Nashville, Tennessee, 37212, United States

  • Site Number - 1576

    Monroe, New York, 10950, United States

  • Site Number - 1577

    Asheville, North Carolina, 28803, United States

  • Site Number - 1578

    San Antonio, Texas, 02114, United States

  • Site Number - 1579

    Macon, Georgia, 31210, United States

  • Site Number - 1580

    Florence, Kentucky, 65613, United States

  • Site Number - 1581

    Jacksonville, Florida, 32204-1177, United States

  • Site Number - 1582

    Jacksonville, Florida, 48334, United States

  • Site Number - 1583

    Canton, Ohio, 44718, United States

  • Site Number - 1586

    Wilmington, North Carolina, 28401, United States

  • Site Number - 1587

    Huntington Beach, California, 92647, United States

  • Site Number - 1588

    Orange, California, 92868, United States

  • Site Number - 1589

    Metairie, Louisiana, 70006, United States

  • Site Number - 1590

    Ocoee, Florida, 34761, United States

  • Site Number - 1591

    Miami, Florida, 78240, United States

  • Site Number - 1592

    Nashville, Tennessee, 37203, United States

  • Site Number - 1593

    Bellaire, Texas, 77401, United States

  • Site Number - 1594

    Gulfport, Mississippi, 33136, United States

  • Site Number - 1595

    Flint, Michigan, 48532, United States

  • Site Number - 1596

    Sandy City, Utah, 84093, United States

  • Site Number - 1597

    Houston, Texas, 77089, United States

  • Site Number - 3103

    Bydgoszcz, Kuyavian-Pomeranian Voivodeship, 85-605, Poland

  • Site Number - 3252

    Prague, 190 14, Czechia

  • Site Number - 3254

    Náchod, 547 01, Czechia

  • Site Number - 4552

    Daegu, 42415, South Korea

  • Site Number - 4553

    Gyeonggi-do, 10326, South Korea

  • Site Number - 4650

    Ogre, LV5001, Latvia

  • Site Number - 4653

    Riga, LV-1050, Latvia

  • Site Number - 4654

    Sigulda, LV-2150, Latvia

  • Site Number - 5150

    Southport, Queensland, 4222, Australia

  • Site Number - 5152

    South Brisbane, Queensland, 4101, Australia

  • Site Number - 5650

    Varna, 9000, Bulgaria

  • Site Number - 5651

    Varna, 9020, Bulgaria

  • Site Number - 5653

    Sliven, 8800, Bulgaria

  • Site Number - 5654

    Varna, 9020, Bulgaria

  • Site Number - 5655

    Smolyan, 4700, Bulgaria

  • Site Number - 5656

    Sofia, 1431, Bulgaria

  • Site Number -1514

    Englewood, Colorado, 80113, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.